ACM
IRWD icon

Acrisure Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Acrisure Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,406
Closed -$290K – 317
2022
Q4 		$290K Buy
+23,406
New +$266K 0.32% 129

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Acrisure Capital Management's IRWD Position: Q1 2023 in Review

Acrisure Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2023, closing a stake of 23,406 shares — an estimated $290K sold.

Acrisure Capital Management first reported a position in IRWD in Q4 2022 and held it in 1 quarter. The position peaked at $290K in Q4 2022. 254 funds tracked by Wall St. Rank hold IRWD as of Q1 2023.

  • Acrisure Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Acrisure Capital Management sold 23,406 Ironwood Pharmaceuticals shares in Q1 2023, an estimated $290K.
  • Acrisure Capital Management first reported a position in Ironwood Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Acrisure Capital Management's Ironwood Pharmaceuticals position peaked at $290K in Q4 2022.
  • 254 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2023.

Based on Acrisure Capital Management's 13F filing for Q1 2023, filed 15 May 2023.